An integrin-targeted photoactivatable Pt(IV) complex as a selective anticancer pro-drug: synthesis and photoactivation studies.

Abstract

A new anticancer agent based on the conjugation of a photoactivatable Pt(IV) pro-drug to a cyclic RGD-containing peptide is described. Upon visible light irradiation, phototoxicity was induced preferentially in SK-MEL-28 melanoma cancer cells overexpressing αVβ3 integrin compared to control DU-145 human prostate carcinoma cells.

• Authors: Albert Gandioso, Evyenia Shaili, Anna Massaguer, Gerard Artigas, Alejandro González-Cantó, Julie A Woods, Peter J Sadler, Vicente Marchán
• Journal: Chemical communications (Cambridge, England) (Chem Commun (Camb)) Vol. 51 Issue 44 Pg. 9169-72 (Jun 04 2015) ISSN: 1364-548X [Electronic] England
• PMID: 25947177 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Integrin alphaVbeta3
• Organoplatinum Compounds
• Peptides, Cyclic
• Prodrugs
• Receptors, Vitronectin
• integrin alphaVbeta5
• Platinum

Topics

• Antineoplastic Agents (chemistry, pharmacology, radiation effects)
• Cell Line, Tumor
• Humans
• Integrin alphaVbeta3 (metabolism)
• Light
• Organoplatinum Compounds (chemistry, pharmacology, radiation effects)
• Peptides, Cyclic (chemistry, pharmacology, radiation effects)
• Platinum (metabolism)
• Prodrugs (chemistry, pharmacology, radiation effects)
• Receptors, Vitronectin (metabolism)